{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:30:41Z","timestamp":1764937841853,"version":"3.37.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-024-06150-8","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T14:06:21Z","timestamp":1735567581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation"],"prefix":"10.1007","author":[{"given":"Ryuta","family":"Kubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Harigae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"6150_CR1","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","volume":"15","author":"Y Bastion","year":"1997","unstructured":"Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, Bryon PA, Coiffier B (1997) Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587\u20131594. https:\/\/doi.org\/10.1200\/JCO.1997.15.4.1587","journal-title":"J Clin Oncol"},{"key":"6150_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/1097-0142(19830801)52:3<393::aid-cncr2820520302>3.0.co;2-m","volume":"52","author":"AJ Garvin","year":"1983","unstructured":"Garvin AJ, Simon RM, Osborne CK, Merrill J, Young RC, Berard CW (1983) An autopsy study of histologic progression in non-Hodgkin\u2019s lymphomas. 192 cases from the National Cancer Institute. Cancer 52:393\u2013398. https:\/\/doi.org\/10.1002\/1097-0142(19830801)52:3%3c393::aid-cncr2820520302%3e3.0.co;2-m","journal-title":"Cancer"},{"key":"6150_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","volume":"126","author":"ND Wagner-Johnston","year":"2015","unstructured":"Wagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, Friedberg JW, Bartlett NL (2015) Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood 126:851\u2013857. https:\/\/doi.org\/10.1182\/blood-2015-01-621375","journal-title":"Blood"},{"key":"6150_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","volume":"125","author":"C Casulo","year":"2015","unstructured":"Casulo C, Burack WR, Friedberg JW (2015) Transformed follicular non-Hodgkin lymphoma. Blood 125:40\u201347. https:\/\/doi.org\/10.1182\/blood-2014-04-516815","journal-title":"Blood"},{"key":"6150_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00277-017-3151-2","volume":"97","author":"T Fischer","year":"2018","unstructured":"Fischer T, Zing NPC, Chiattone CS, Federico M, Luminari S (2018) Transformed follicular lymphoma. Ann Hematol 97:17\u201329. https:\/\/doi.org\/10.1007\/s00277-017-3151-2","journal-title":"Ann Hematol"},{"key":"6150_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1182\/hematology.2020000115","volume":"2020","author":"S Smith","year":"2020","unstructured":"Smith S (2020) Transformed lymphoma: what should I do now? Hematol Am Soc Hematol Educ Program 2020:306\u2013311. https:\/\/doi.org\/10.1182\/hematology.2020000115","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"6150_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jager U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak O, Salles G, Maziarz RT, Investigators J (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380:45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"key":"6150_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"39","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 39:839\u2013852. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet"},{"key":"6150_CR9","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"6150_CR10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1182\/blood-2017-08-752121","volume":"131","author":"M Smith","year":"2018","unstructured":"Smith M, Zakrzewski J, James S, Sadelain M (2018) Posttransplant chimeric antigen receptor therapy. Blood 131:1045\u20131052. https:\/\/doi.org\/10.1182\/blood-2017-08-752121","journal-title":"Blood"},{"key":"6150_CR11","doi-asserted-by":"publisher","unstructured":"stem cell transplantation in B-cell lymphoproliferative disorders: are they really autologous or allogenic cell therapies? Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13184664","DOI":"10.3390\/cancers13184664"},{"key":"6150_CR12","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.17544","volume":"195","author":"K Sanber","year":"2021","unstructured":"Sanber K, Savani B, Jain T (2021) Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. Br J Haematol 195:660\u2013668. https:\/\/doi.org\/10.1111\/bjh.17544","journal-title":"Br J Haematol"},{"key":"6150_CR13","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507\u20131517. https:\/\/doi.org\/10.1056\/NEJMoa1407222","journal-title":"N Engl J Med"},{"key":"6150_CR14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517\u2013528. https:\/\/doi.org\/10.1016\/S0140-6736(14)61403-3","journal-title":"Lancet"},{"key":"6150_CR15","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG (2016) CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 126:2123\u20132138. https:\/\/doi.org\/10.1172\/JCI85309","journal-title":"J Clin Invest"},{"key":"6150_CR16","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC (2017) Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129:3322\u20133331. https:\/\/doi.org\/10.1182\/blood-2017-02-769208","journal-title":"Blood"},{"key":"6150_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378:449\u2013459. https:\/\/doi.org\/10.1056\/NEJMoa1709919","journal-title":"N Engl J Med"},{"key":"6150_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378:439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"key":"6150_CR19","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/s41375-019-0476-y","volume":"33","author":"T Jain","year":"2019","unstructured":"Jain T, Sauter CS, Shah GL, Maloy MA, Chan J, Scordo M, Avecilla ST, Batlevi Y, Dahi PB, Batlevi CW, Lia Palomba M, Giralt SA, Perales MA (2019) Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed\/refractory B cell non-Hodgkin lymphoma. Leukemia 33:2540\u20132544. https:\/\/doi.org\/10.1038\/s41375-019-0476-y","journal-title":"Leukemia"},{"key":"6150_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bjh.17121","volume":"192","author":"F Lutfi","year":"2021","unstructured":"Lutfi F, Holtzman N, Siglin J, Bukhari A, Mustafa Ali M, Kim D, Sanchez-Petitto G, Gottlieb D, Ruehle K, Hutnick E, Gahres N, Hankey K, Lee S, Kocoglu M, Yared J, Hardy N, Rapoport A, Dahiya S (2021) Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed\/refractory large B-cell lymphoma. Br J Haematol 192:212\u2013216. https:\/\/doi.org\/10.1111\/bjh.17121","journal-title":"Br J Haematol"},{"key":"6150_CR21","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1182\/bloodadvances.2020001797","volume":"4","author":"RK Das","year":"2020","unstructured":"Das RK, O\u2019Connor RS, Grupp SA, Barrett DM (2020) Lingering effects of chemotherapy on mature T cells impair proliferation. Blood Adv 4:4653\u20134664. https:\/\/doi.org\/10.1182\/bloodadvances.2020001797","journal-title":"Blood Adv"},{"key":"6150_CR22","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00277-014-2135-8","volume":"93","author":"R Garcia Munoz","year":"2014","unstructured":"Garcia Munoz R, Izquierdo-Gil A, Munoz A, Roldan-Galiacho V, Rabasa P, Panizo C (2014) Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol 93:1879\u20131887. https:\/\/doi.org\/10.1007\/s00277-014-2135-8","journal-title":"Ann Hematol"},{"key":"6150_CR23","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1038\/bcj.2015.86","volume":"5","author":"H Saito","year":"2015","unstructured":"Saito H, Maruyama D, Maeshima AM, Makita S, Kitahara H, Miyamoto K, Fukuhara S, Munakata W, Suzuki T, Kobayashi Y, Taniguchi H, Tobinai K (2015) Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J 5:e362. https:\/\/doi.org\/10.1038\/bcj.2015.86","journal-title":"Blood Cancer J"},{"key":"6150_CR24","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, Oluwole OO, Reagan PM, Lekakis LJ, Lin Y, Sherman M, Better M, Go WY, Wiezorek JS, Xue A, Bot A (2020) Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4:4898\u20134911. https:\/\/doi.org\/10.1182\/bloodadvances.2020002394","journal-title":"Blood Adv"},{"key":"6150_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.23.01097","volume":"42","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G, Navarro V, Martin-Lopez AA, Rejeski K, Kwon M, Jalowiec KA, Amat P, Reguera-Ortega JL, Gallur L, Blumenberg V, Gutierrez-Herrero S, Roddie C, Benzaquen A, Delgado-Serrano J, Sanchez-Salinas MA, Bailen R, Carpio C, Lopez-Corral L, Hernani R, Bastos M, O\u2019Reilly M, Martin-Martin L, Subklewe M, Barba P (2024) Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. J Clin Oncol 42:205\u2013217. https:\/\/doi.org\/10.1200\/JCO.23.01097","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06150-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06150-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06150-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T11:19:21Z","timestamp":1739359161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06150-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":25,"alternative-id":["6150"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06150-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"16 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for the publication of any potentially identifable data included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}